- Home
- PMAX vs BDRX Comparison
PMAX vs BDRX Comparison
Compare PMAX & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMAX | BDRX |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.0M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMAX | BDRX |
|---|---|---|
| Price | $2.79 | $2.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 2.8M |
| Earning Date | 09-23-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,799,100.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $2.55 |
| 52 Week High | $22.00 | $92.00 |
Technical Indicators
Market Signals| Indicator | PMAX | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 38.31 |
| Support Level | $2.17 | $4.55 |
| Resistance Level | $2.94 | $7.22 |
| Average True Range (ATR) | 0.22 | 1.32 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 60.00 | 0.84 |
Price Performance
Historical ComparisonAbout PMAX Powell Max Limited
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.